Pulmonary thromboembolism: Long-term clinical course and clinical epidemiology;Tromboembolismo pulmonar: Evolución a largo plazo y epidemiología clínica

Anales de Medicina Interna

Volumn 20, Issue 9, 2003, Pages 451-456

  Echegaray Agara, M ^a   Alonso Martínez, José Luis ^a,b   Urbieta Echezarreta, M A ^a   Abinzano Guillen M L ^a   Gonzalez Arencibia C ^a   Solano Remirez M ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b NONE   (Spain)

Author keywords

Clinical epidemiology; Long term clinical course; Pulmonary thromboembolism; Venous thromboembolic disease

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; BLEEDING; BLOOD TRANSFUSION; BREAST CANCER; CAUSE OF DEATH; CLINICAL OBSERVATION; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DISEASE COURSE; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; KIDNEY CANCER; LIVER CANCER; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVARY CANCER; PROSPECTIVE STUDY; PROSTATE CANCER; RELAPSE; SURVIVAL;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; SURVIVAL RATE; TIME FACTORS;

EID: 0142105476     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dalen JE. Pulmonary embolism; What have we learned since Virchow?. Natural history, pathophysiology, and diagnosis. Chest 2002; 122: 1440-56
2. Musset D, Parent F, meyer G, maitre S, Girard P, Ieroyer C, et al. Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentric outcome study. Lancet 2002; 360: 1914-20.
3. Kruip MJHA, Slob MJ, Schijen JHEM, van der Heul C Büller HR. Use of a clinical decision rule in combination with D-Dimer concentration in diagnostic work up of patients with suspected pulmonary embolism. Arch Intern Med 2002; 162: 1631-5.
4. Chagnon I, Bounameaux H, Aujesky D, Roy PM, Gourdier AL, Cornuz J, et al. Comparison of two clinical prediction rules and implicit assessment among patients with suspected pulmonary embolism. Am J Med 2002; 113: 269-75.
5. Kelly J, Rudd A, Lewis RR, Hunt BJ. Plasma D dimers in the diagnosis of venous thromboembolism. Arch Intern Med 2002; 162: 747-54.
6. Home III MDK. The dark side of deep venous thrombosis: the failure of anticoagulation. Am J Med 2001; 110: 589-90.
7. Prins MH, Hettiarachchi RJ, Lensing AW, Hirsh J. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see?. Thromb Haemost 1997; 78: 121-5.
8. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Throm Res 2001; 102: 187-94.
9. Landefeld CS, Beyth R. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993;95:315-328.
10. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolism and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. Clin Oncol 2000; 18: 3078-83.
11. Prandoni P. Long-term clinical course of proximal deep venous thrombosis and detection of reccurent thrombosis. Semin Thromb Haemost 2001; 27: 9-13.
12. Hansson PO, S:orbo J, Ericksson H. Recurrent venous thromboembolism after deep venous thrombosis. Arch Intern Med 2000; 160: 769-74.
13. Agnelli G, Prandoni P, Santamaría MG, Bagatella P, Iorio A, Bazzan M, et al. Three months versus one year of oral anticoagulation for idiopathic deep venous thrombosis. Warfarin optimal duration italian trial investigators. N Engl J Med 2001; 345: 165-9.
14. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Cocheri S. Risk of venous thromboembolism recurrence: high negative prediction value of D-Dimer performed after oral anticvoagulation is stopped. Throm Haemost 2002; 87: 7-12.
15. Kruijer PM, Hutten BA, Prins MH, Büller HR. prediction of the risk of bleeding during anticoagulation for venous thromboembolism. Arch Intern Med 1999; 159: 457-60.
16. Douketis JD, Keaton C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.
17. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term cliical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7
18. Beyth RJ, Coher AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995; 155: 1031-7.
19. Prandoni P, Pccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84: 437-45.
20. Piccioli A, Prandoni P. Venous thrombosis as first manifestation of cancer. Acta Haematol 2001; 106: 13-7.
21. Rickles FR, Lovine MN. Venous thromboembolism in malignancy and malignancy in occult thromboembolism. Haemostasis 1998; (Supl) 3: 43-9.
22. Prandoni P. Cancer and thromboembolic disease: How important is the risk of thrombosis. Cancer Trat Rev 2002; 28: 133-6.
23. Monreal M, Prandoni P. Venous thrombosis as first manifestation of cancer. Semin Thromb Hemost 1999; 2s: 131-6.
24. Monreal M, Fernández-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997; 78: 1316-8.
25. Shulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulant trial. N engl J Med 2000; 342: 1953-8.
26. Ornstein D, Zacharsky L. The use of heparin for treating human malignancies. Haemostasis 1999; 29 (Supl. s1): 48-60.
27. Engelberg H. Actions of heparin that may affect the malignancy process. Cancer 1999; 85: 257-72.